Updates are available Correction dated 2020-01-16
Click to view Correction: https://doi.org/10.1007/s00415-019-09694-2
-
Authors
Ness, Nils-Henning
Schriefer, Dirk
Haase, Rocco
Ettle, Benjamin
Cornelissen, Christian
Ziemssen, Tjalf http://orcid.org/0000-0001-8799-8202
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 21 October 2019
Revised: 11 December 2019
Accepted: 12 December 2019
First Online: 17 December 2019
Change Date: 16 January 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. The captions of Fig. 2 and Fig. 3 are mismatched.
Compliance with ethical standards
:
: NHN has received funding for research from Novartis. DS has nothing to disclose. RH has received speaker fee from Sanofi and travel grants from Celgene. BE is an employee of Novartis. CC was an employee of Novartis at the time of this study, and now an employee of Siemens. TZ received personal compensation from Almirall, Biogen, Bayer, Celgene, Novartis, Roche, Sanofi, Teva for consulting and speaking services and he is the section editor for BMC Neurology. Additionally, he received financial support for research activities from BAT, Biogen Novartis, Teva and Sanofi.
: Approval for PANGAEA and PEARL were obtained from independent, local competent ethics committees.
: All patients provided written informed consent for the collection of clinical and health economic information.
